In ATTR-amyloidosis, starting ATTR-stabilizing treatment at earlier stages of the disease (New York Heart Association (NYHA) I and II) leads to an improvement in prognosis while patients with advanced cardiac involvement (NYHA III) do no longer benefit [7•]. This evidence concerns the gene TTR and amyloidosis.